Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique

► We assess the cost-effectiveness of an additional birth dose of Hepatitis B vaccine. ► The birth dose is highly cost-effective with an ICER of 250.95 US$ per DALY averted. ► Outcome shows sensitive to parameter variation in sensitivity analysis. ► Most sensitive to 'prevalence of HBV' and 'transition probability from chronic HBV to liver cancer'.